PDBsum entry 5i46

Hydrolase/hydrolase inhibitor

PDB id: 5i46

Contents

Protein chains

254 a.a.

55 a.a.

Ligands

67O

SO4 ×3

MES

Metals

_CA

Waters ×209

PDB id:

5i46

Name:

Hydrolase/hydrolase inhibitor

Title:

Factor viia in complex with the inhibitor (2r,15r)-2-[(1- aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13- oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19- hexaene-3,12-dione

Structure:

Coagulation factor vii (heavy chain). Chain: h. Synonym: proconvertin,serum prothrombin conversion accelerator,spca. Engineered: yes. Coagulation factor vii (light chain). Chain: l. Synonym: proconvertin,serum prothrombin conversion accelerator,spca. Engineered: yes

Source:

Homo sapiens. Human. Organism_taxid: 9606. Gene: f7. Expressed in: cricetinae. Expression_system_taxid: 10026. Expression_system_taxid: 10026

Resolution:

2.06Å R-factor: 0.218 R-free: 0.239

Authors:

A.Wei

Key ref:

P.W.Glunz et al. (2016). Atropisomer Control in Macrocyclic Factor VIIa Inhibitors. J Med Chem, 59, 4007-4018. PubMed id: 27015008 DOI: 10.1021/acs.jmedchem.6b00244

Date:

11-Feb-16 Release date: 22-Jun-16

Protein chain

P08709  (FA7_HUMAN) -  Coagulation factor VII from Homo sapiens

Seq: 466 a.a.

Struc: 254 a.a.

Protein chain

P08709  (FA7_HUMAN) -  Coagulation factor VII from Homo sapiens

Seq: 466 a.a.

Struc: 55 a.a.

Enzyme reactions

• Enzyme class: Chains H, L: E.C.3.4.21.21 - coagulation factor VIIa.
• Reaction: Hydrolyzes one Arg-|-Ile bond in factor X to form factor Xa.

DOI no: 10.1021/acs.jmedchem.6b00244

J Med Chem 59:4007-4018 (2016)

PubMed id: 27015008

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.

P.W.Glunz, L.Mueller, D.L.Cheney, V.Ladziata, Y.Zou, N.R.Wurtz, A.Wei, P.C.Wong, R.R.Wexler, E.S.Priestley.

ABSTRACT

Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.